Oral Semaglutide Dosing for Type 2 Diabetes
Ozempic (semaglutide) is NOT available in an oral formulation—only as a subcutaneous injection. The oral formulation of semaglutide is marketed under a different brand name (Rybelsus), not Ozempic 1.
Subcutaneous Ozempic Dosing (Injectable)
For subcutaneous semaglutide (Ozempic), the FDA-approved dosing regimen is 2:
- Starting dose: 0.25 mg once weekly for 4 weeks (not for glycemic control—this is a dose escalation period)
- Maintenance dose: Increase to 0.5 mg once weekly after 4 weeks
- Maximum dose: If additional glycemic control is needed, increase to 1 mg once weekly after at least 4 weeks on 0.5 mg, and potentially to 2 mg once weekly if further control is required
Administration: Inject subcutaneously once weekly at any time of day, with or without meals 1.
No renal dose adjustments required 1.
Oral Semaglutide Dosing (Rybelsus—Different Product)
If you're asking about oral semaglutide (which is Rybelsus, not Ozempic), the dosing is 1:
- Starting dose: 3 mg once daily for 30 days
- Maintenance dose: Increase to 7 mg once daily after 30 days
- Maximum dose: If additional glycemic control is needed, increase to 14 mg once daily after at least 30 days on 7 mg 3, 4
Critical Administration Requirements for Oral Semaglutide
Oral semaglutide must be taken under very specific conditions to ensure adequate absorption 1, 5:
- Take at least 30 minutes before the first food, beverage, or other oral medications of the day
- Take with no more than 120 mL (4 ounces) of plain water only
- Overnight fasting before the dose is optimal—shorter fasting periods (2-6 hours) result in significantly reduced drug exposure (AUC reduced by 57-88% and Cmax reduced by 56-89%) 5
- After taking the tablet, wait at least 30 minutes before eating, drinking, or taking other medications
Common Pitfall
Do not confuse Ozempic (subcutaneous) with Rybelsus (oral)—they are different products with different dosing schedules and administration requirements. Prescribing "oral Ozempic" is incorrect terminology that could lead to medication errors.
Clinical Context
Both formulations are GLP-1 receptor agonists with proven cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease 6, 7, 8. Prioritize these agents in patients with:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Heart failure
- Chronic kidney disease with eGFR ≥30 mL/min/1.73 m² 1, 7
- High cardiovascular risk factors
The subcutaneous formulation generally provides greater glycemic efficacy and weight loss compared to the oral formulation at equivalent doses 9, though both are effective options depending on patient preference and tolerability.